X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
RCT2100 is an inhaled mRNA-based therapy developed using our novel SORT lipid nanoparticle delivery platform. It is being developed for the treatment of cystic fibrosis.
Lead Product(s): RCT2100
Therapeutic Area: Genetic Disease Product Name: RCT2100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2024
Details:
The collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary selective Organ Targeting lipid nanoparticle to precisely correct one or more cystic fibrosis disease-causing gene mutations.
Lead Product(s): CRISPR-based Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: Intellia Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 15, 2024
Details:
RCT1100 is an inhaled mRNA therapy designed to deliver and express DNAI1 mRNA in target cells. It is under phase 1 clinical development for the treatment of Primary Ciliary Dyskinesia.
Lead Product(s): RCT1100
Therapeutic Area: Rare Diseases and Disorders Product Name: RCT1100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
The proceeds will advance ReCode’s proprietary Selective Organ Targeting lipid nanoparticle pipeline, including Phase 1 trial of RCT1100 for primary ciliary dyskinesia and RCT2100, its cystic fibrosis candidate.
Lead Product(s): RCT1100
Therapeutic Area: Rare Diseases and Disorders Product Name: RCT1100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bioluminescence Ventures
Deal Size: $260.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing September 19, 2023
Details:
RCT1100 is a first-in-class, mRNA-based genetic medicine for the treatment of people with primary ciliary dyskinesia (PCD) caused by pathogenic mutations in the DNAI1 gene that encodes a protein essential for ciliary movement.
Lead Product(s): RCT1100
Therapeutic Area: Rare Diseases and Disorders Product Name: RCT1100
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2023
Details:
ReCode is developing an inhaled ARCT-032 (mRNA therapy), designed to provide a correct copy of the cystic fibrosis transmembrane conductance regulator (CFTR) mRNA to lung cells to make a functional CFTR protein.
Lead Product(s): mRNA-based Therapy
Therapeutic Area: Genetic Disease Product Name: ARCT-032
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: The Cystic Fibrosis Foundation
Deal Size: $15.0 million Upfront Cash: Undisclosed
Deal Type: Funding January 10, 2023
Details:
AskBio will combine its synthetic DNA and gene editing nucleases with ReCode's selective organ targeting LNP technology to potentially create an all-in-one solution that enables full gene insertion by delivering with precision both the gene editing tool and DNA.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Recipient: AskBio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 09, 2023
Details:
Proceeds from the financing will be used to fund the diversification of ReCode’s pipeline into central nervous system, liver, and oncology indications, while continuing to advance lead mRNA programs for primary ciliary dyskinesia and cystic fibrosis into the clinic.
Lead Product(s): SORT LNP-based DNAI1 mRNA Therapeutic
Therapeutic Area: Rare Diseases and Disorders Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Leaps by Bayer
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 29, 2022
Details:
Study confirms the ability of ReCode’s SORT Lipid Nanoparticle, platform to deliver optimized, functional CFTR mRNA as an aerosol directly to specific cell targets.
Lead Product(s): LNP-based mRNA Therapeutics
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 18, 2022
Details:
Results from a non-human primate model show that ReCode’s SORT LNP-formulated mRNA is well-tolerated and can be nebulized and delivered directly to the lungs as an inhaled aerosol without significant exposure to other tissues.
Lead Product(s): LNP-encapsulated mRNA Therapy
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
